WAC and ASP of Herceptin (trastuzumab) biosimilars in the US 2022
As of 2022, biosimilar Herzuma (trastuzumab-pkrb) launched at an average sales price of six percent less than Herceptin's ASP, while biosimilar Trazimera (trastuzumab-qyyp) launched at an average sales price of 19 percent less than Herceptin's. This statistic illustrates the wholesale acquisition cost and average sales price of Herceptin (trastuzumab) biosimilars in the United States.